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A B S T R A C T   
Commercially available bovine-specific assays are limited in number, and multiplex assays for this species are 
rare. Our objective was to develop a multiplex assay for the bovine inflammatory cytokines IL-1β, IL-6, and TNF- 
α using the Meso Scale Discovery U-PLEX platform. "Do-It-Yourself" ELISA kits that contained polyclonal anti-
bodies, both unlabeled and biotinylated, and the specific recombinant bovine cytokine standard, were purchased 
for each of these three cytokines. The biotinylated antibodies were coupled to linkers that bind to specific lo-
cations within each well of the U-PLEX plate. Unique linkers were used for each of the cytokines. The unlabeled 
antibodies were conjugated with electrochemiluminescent labels to serve as detection antibodies. Each cytokine 
assay was optimized individually prior to performing an optimization on the multiplex assay containing reagents 
for all three cytokines. To calculate cytokine concentrations, standard curves were developed using the re-
combinant cytokines and were run concurrently on each plate. Standard curves for IL-1β and TNF-α were run at 
concentrations ranging from 0 to 50,000 pg/mL, and for IL-6 from 0 to 10,000 pg/mL. The average lowest level 
of detection concentration measured by the standard curves were 5.3 pg/mL, 0.92 pg/mL, and 22.34 pg/mL for 
IL-1β, IL-6, and TNF-α respectively, as determined by data from seven plates containing bovine plasma samples 
from a combination of healthy and diseased cattle. The U-PLEX platform was a viable means to develop custom 
analyte- and species-specific multiplex assays using privately developed or purchased sets of commercially 
available reagents.   
1. Introduction 
Multiplex immunoassays are an efficient alternative to running in-
dividual assays for each metabolite of interest. Less sample can be uti-
lized which is important for rare or difficult to obtain samples, much less 
time is spent on setting up plates and dilutions, and variation between 
different assays can be reduced by running them concurrently rather 
than over different plates and/or days (Dudal et al., 2014; Lea et al., 
2011; Leng et al., 2008). Unfortunately, there are few multiplex bovine 
cytokine assays commercially available “off the shelf”. These include the 
Milliplex® Bovine Cytokine/Chemokine 15-plex Panel 1 which includes 
IFNγ, IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-17A, MIP-1α, IL-36RA, IP-10, 
MCP-1, MIP-1β, TNF-α, and VEGF-A (https://www.emdmillipore.com); 
the Abcam Bovine Cytokine Antibody Array which includes IFNα, IFNγ, 
IL-13, IL-1α, IL-1F5, IL-21, IP-10, MIG, MIP-1β, and TNF-α (https:// 
Abcam.com); and the RayBiotech Quantibody® Bovine Cytokine Array 
1 which includes ANGPT1, CCL5, CD40 L, DCN, IFNβ1, IL-10, IL-17A, 
IL-18, IL-1-β, and LIF (https://www.raybiotech.com/). This “one-size--
fits-all” selection of metabolite assays may result in researchers paying 
for more information than they require or may not include the specific 
metabolite assays needed. 
Platforms currently available for multiplexing include bead-based 
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systems - also known as multiplexed bead immunoassays (MBIA) or 
bead-based multiplexed assays (BBMA) - where antibodies against spe-
cific analytes are bound to fluorescent beads and the samples are 
analyzed by a dual-laser, flow-based reader (Burgos-Ramos et al., 2012), 
glass slide arrays where the antibodies are bound to glass slides which 
are analyzed on specialized plate scanners, and the Meso Scale Discov-
ery (MSD) platform where antibodies are bound within wells of a 
96-well plate that includes electrodes that when stimulated in the 
specialized plate reader, results in electrochemiluminescent (ECL) 
emission. These different systems all have pros and cons as reviewed by 
Dudal et al. (2014) and Tighe et al. (2015), however one of the greatest 
considerations and costs is generally the “reader” required for each 
platform. 
As with the ELISA, the gold standard of protein assay systems (Bur-
gos-Ramos et al., 2012; Dernfalk et al., 2007; Dudal et al., 2014; Leng 
et al., 2008), all the multiplex systems available require the use of an-
tibodies specific to the proteins being measured. Great progress in 
developing immune reagents such as antibodies for the study of veteri-
nary immunology has been made through the efforts of individual 
research laboratories and groups such as the US Veterinary Immune 
Reagent Network (https://www.umass.edu/vetimm/) and The Immu-
nological Toolbox maintained in the UK by The Pirbright Institute 
(https://www.immunologicaltoolbox.co.uk/). Researchers test 
lab-developed antibodies from domestic animals and in cooperation 
with companies such as Kingfisher Biotech (St. Paul, MN), these reagents 
are made commercially available to other research laboratories. Also 
available are "Do-It-Yourself" ELISA kits containing the antibody pairs 
required to perform a sandwich ELISA and a recombinant protein to 
serve as the standard/calibrator. Utilizing these kits eliminates the time 
and cost of identifying antibody pairs that bind to different epitopes thus 
allowing one to serve as the binding antibody and one as the reporter 
antibody. 
Christopher-Henning et al., state “…it is useful to have multiplexed 
cytokine assays that can objectively assess the biological immune re-
sponses to pathogens, vaccines, and therapeutics or other interventions 
for controlling animal diseases.” (2012) By adapting "Do-It-Yourself" 
ELISA kits, we developed a multiplex assay for the bovine inflammatory 
cytokines IL-1β, IL-6, and TNF-α using the MSD U-PLEX platform which 
can concurrently perform up to ten separate assays in a single well. The 
MSD U-PLEX platform utilizes a unique linker technology to capture 
biotinylated reagents at specific locations within the wells of microtiter 
plates, and users can develop customized multiplex assays at the bench. 




Two types of samples were used as unknowns to develop the multi-
plex assay. The first samples were tissue culture supernatants from 
bovine monocytes that were isolated from three feedlot animals and 
either treated with LPS (N = 3) to stimulate cytokine production or were 
untreated (N = 3). Monocytes were isolated as previously described 
(Chitko-McKown et al., 2004) and were cultured in RPMI 1640 (Gibco, 
Thermo Fisher Scientific, Grand Island, NY; 22,400,105) containing 5% 
FBS (HyClone Laboratories, Logan, UT; 16777− 530) and anti-
biotic/antimycotic (Thermo Fisher Scientific; 15,240,062). LPS (055:B5, 
Sigma-Aldrich, St. Louis, MO; L6529) was added to the media at a 
concentration of 1 μg/mL, and the cells cultured for 24H at 37℃ with 
5% CO2. The second set were plasma samples obtained from cattle 
enrolled on a longitudinal study of bovine respiratory disease complex 
(BRDC; DeDonder et al., 2015). These samples were from both healthy 
animals (N = 28) and those suffering from respiratory disease (N = 28). 
Plasma was collected from blood obtained from four time points from 
the healthy animals (D0, D1, D9, and D28), and six time points (D0, D1, 
D 9, date of diagnosis and treatment for respiratory disease, 5 days after 
diagnosis of respiratory disease, and D28). Isolation of bovine mono-
cytes for stimulation with LPS was approved by the USMARC Institu-
tional Animal Care and Use Committee (#2.1), and blood collection 
from the BRDC study cattle was approved by the KSU Institutional An-
imal Care and Use Committee (#3338). 
2.2. Multiplex U-PLEX assay development 
2.2.1. Reagent preparation 
The U-Plex Development Pack (Catalog # K15228N-2) was pur-
chased from MSD (Rockville, MD) and contained 3-Assay SECTOR Plates 
(96-well format), a set of U-PLEX linkers (for well locations 1, 3, and 10), 
U-PLEX Stop Solution, and 4X Read Buffer T. MSD SULFO-TAG Conju-
gation Pack (#R31AA-1) which utilizes NHS-Ester coupling chemistry, 
was also used to conjugate detection antibodies with SULFO-TAG, 
following manufacturer’s instructions. “Do-It-Yourself ELISA” kits for 
Bovine TNF-α, IL-6, and IL-1β were purchased from Kingfisher Biotech, 
Inc., (Saint Paul, MN, USA; DIY0675B-003, DIY0670B-003, DIY1111B- 
003). Additional MSD Diluents used in the assays were purchased 
separately and included Diluent 2 (#R51BB-3), Diluent 7 (#R54BB-3) 
which were tested as diluents for the standard curves and the samples, 
and Diluent 8 (#R54BA-3) used to dilute the detection antibody mix. 
The Biotinylated polyclonal antibodies from the “Do-It-Yourself 
ELISA” kits which would normally be used as reporter antibodies in a 
traditional ELISA were instead used as capture antibodies in the U-PLEX 
assay. In order to specifically bind to one of the 10 binding locations 
within each U-PLEX plate well, each antibody was diluted in 1% BSA/ 
PBS-T to a concentration of 10ug/mL and coupled with a unique MSD 
Linker as per the manufacturer’s instructions to result in three coating 
solutions with final antibody concentrations of 1μg/mL. For singleplex 
coating solutions, linked antibodies were diluted with MSD Stop Solu-
tion 10-fold to 1μg/mL final concentration; for multiplex coating solu-
tion, the three linked antibodies were combined and diluted with MSD 
Stop Solution so that the final concentration of each antibody was 1μg/ 
mL. Linker 1 was coupled with biotinylated anti-bovine TNF-α poly-
clonal antibody, Linker 3 was coupled with biotinylated anti-bovine IL- 
1β polyclonal antibody, and Linker 10 was coupled with biotinylated 
anti-bovine IL-6 polyclonal antibody. 
Recombinant protein standards/calibrators for all three cytokines 
were reconstituted at 5μg/mL in 1% BSA/PBS-T. In addition to prepar-
ing individual calibrators, a blended calibrator was created by 
combining the three recombinant proteins in a sub-stock at a concen-
tration of 50,000 pg/mL each. The highest calibrator point (STD1) was 
prepared at a concentration of 10,000 pg/mL and 4-fold serial dilutions 
were carried out to a concentration of 2.44 pg/mL (STD7). The lowest 
calibrator point (STD8) was 1% BSA/PBS-T buffer only. 
The “Do-It-Yourself ELISA” kit polyclonal antibodies that would 
traditionally have been used as capture antibodies in a sandwich ELISA 
were used as detection antibodies in the U-PLEX assay. These antibodies 
were buffer exchanged to remove sodium azide using Zeba™ Spin 
Desalting Columns (Thermo Fisher Scientific, Waltham, MA, USA) 
following manufacturer’s Buffer Exchange protocol. Recovered anti-
bodies were then SULFO-TAG conjugated following MSD GOLD SULFO- 
TAG NHS-Ester Conjugation Pack 1 protocol. SULFO-TAG detection 
antibodies were diluted individually and in a multiplex format, all at a 
final concentration of 1μg/mL in 1% BSA/PBS-T. 
2.2.2. Experiment one 
Our first experiment was to test the sensitivity of each cytokine assay 
in singleplex on U-PLEX plates along with comparing the assays in 
multiplex using a simple diluent. Additionally, we sought to test the 
detection antibody cross-reactivity by testing each detection antibody 
individually and with the multiplex assay components. The assay was 
performed following a generic protocol provided in the MSD U-PLEX 
Development pack. All assays described in the following experiments 
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were performed in 8 rows by 12 columns, 96-well U-PLEX plates. 
Standards were run on every plate and all samples and standards were 
run in duplicate. Briefly, MSD 3-Assay 10-Spot SECTOR Plate and re-
agents were equilibrated to RT for 30 min prior to beginning the assay. 
The plate was blocked by adding 150μL 3% BSA prepared in phosphate 
buffered saline with 0.05 % Tween 20 (PBS-T) per well, sealed with 
adhesive plate sealing film and incubated with shaking at 700 RPM at RT 
for 1H on a benchtop microplate shaker. Alternately, plates were 
blocked overnight by adding 150μg/mL 3% BSA/PBS-T per well, sealed, 
and refrigerated overnight at 4 ◦C, with no agitation. 
Blocking solution was removed and wells were washed three times 
with 150μl PBS-T. Fifty μl of coating solution containing capture anti-
bodies coupled to a unique linker for TNF-α was added to columns 1 & 2 
of the plate. Columns 3 & 4 were used for IL-6, and columns 5 & 6 for IL- 
1β. Columns 7–12 were coated with 50 μl containing all three capture 
antibodies. The plate was sealed and incubated for 1H at RT with 
shaking as described above. Plates were then washed three times with 
150 μl wash solution. 
Calibrators were prepared in 1% BSA/PBS-T and 4-fold serial di-
lutions were prepared with a highest calibrator concentration of 
10,000 pg/mL for each recombinant protein. Seven serial dilutions of 
standard were plated in duplicate started with the highest calibrator 
(STD1) in row A, and the lowest concentration in row G (STD7). Row H 
contained 1% BSA/PBS-T only. The individual cytokine standards (50 
μl/well) were plated as described above for the capture antibodies. The 
combined three standards were plated in descending concentrations in 
columns 7–11, and TNF-α STD 3 was plated in column 12 rows A–B, IL-6 
STD 3 in rows C–D, IL-1β STD 3 in rows E–F, and 1% BSA/PBS-T was 
added to rows G–H. The plate was sealed and incubated at RT with 
shaking for 1H, followed by washing 3 times as described above. 
Detection antibodies were added at 1 μg/mL in 25 μl using the 
following format: TNF-α, IL-6, and IL-1β were individually added to 
columns 1–2, 3–4, and 5–6, respectively. The three detection antibodies 
were combined and added to columns 7− 8. The individual detection 
antibodies were also added to columns 9–11 similar to columns 1–6, and 
the combined antibodies were added to column 12. The plate was sealed 
and incubated for 1H at RT with shaking, followed by washing as 
described above. 150μl of 2X Read Buffer T was added to each well of the 
plate which were immediately analyzed on the SQ120 QuickPlex reader 
(MSD). 
2.3. Experiment two 
A second experiment was designed to compare the performance of 
each assay in different diluents and a titration of IL-6 detection antibody 
was performed. Capture antibodies were prepared and added to the 
plate as described for Experiment One followed by incubation for 1H at 
RT with shaking and washing as previously described. Calibrators were 
prepared as described however IL-6 STD 1 for this experiment was 
10,000 pg/mL, and IL-1β and TNF-α STD 1 were increased to 
50,000 pg/mL. Four-fold serial dilutions of the calibrators were per-
formed in 1% BSA/PBS-T and were added to columns 1–6, and cali-
brators serially diluted with Diluent 7 were added to columns 7− 12. 
Plates were sealed, incubated with shaking at RT for 2H and were 
washed as previously described. 
The detection antibody mix was prepared with three different con-
centrations of IL-6 (1.0, 0.5, or 0.25 μg/mL) in two different buffers, 
either 1%BSA/PBS-T or Diluent 8 from MSD. Concentrations of the IL-1β 
and TNF-α antibodies remained at 1μg/mL. The detection antibody mix 
diluted in 1% BSA/PBS was added to columns 1–6, and the mix diluted 
in Diluent 8 was added to columns 7− 12. IL-6 detection antibody was 
1μg/mL for the mixes used in columns 1–2, and 7–8, 0.5μg/mL for the 
mixes used in columns 3–4, and 9–10, and 0.25μg/mL for the mixes used 
in columns 5–6, and 11− 12. The detection antibody mix was added to 
each well at 25μL/well, the plate was sealed and incubated with shaking 
for 1H at RT and was washed as described above followed by the 
addition of 150μL of 2X Read Buffer T to each well of the plate with 
immediate analysis on the SQ120 QuickPlex reader. 
2.4. Experiment three 
We designed this experiment to test the performance of the multiplex 
when using 1% BSA/PBS-T as the diluent as compared to RPMI + 5% 
FBS. Samples tested in this experiment included supernatants from 
bovine monocytes cultured in RPMI 1640 with 5% FBS which were 
either untreated (N = 3) or treated with 1μg/mL LPS (N = 3) to stimu-
late inflammatory cytokine production. As described for Experiments 
One and Two, the capture antibodies were prepared at 10μg/mL in 1% 
BSA/PBS-T, the calibrators were prepared with STD 1 at 50,000 pg/mL 
for IL-1β and TNF-α and 10,000 pg/mL for IL-6. These were diluted in 
either 1% BSA/PBS-T or RMPI + 5%FBS. Supernatant samples were run 
undiluted. Detection antibodies were used at 1μg/mL for IL-1β and TNF- 
α, and at 0.25μg/mL for IL-6. The assay was run as described for Ex-
periments One and Two. 
2.5. Experiment four 
This experiment was designed to test if plasma samples obtained 
from cattle either healthy or suffering from BRDC could be better 
assayed by diluting samples and calibrators with Diluent 2 or Diluent 7. 
The capture antibody mix was prepared with 1% BSA/PBS-T, and the 
detection antibody mix was prepared with Diluent 8. The plasma sam-
ples were assayed neat and at 2-fold, 4-fold, 8-fold, and 16-fold di-
lutions. The assay was run with all other conditions as described for 
Experiment Three. 
2.6. Experiment five 
Two hundred fifty unique bovine plasma samples were run undiluted 
using optimized conditions determined by the prior four experiments to 
determine the percent intra- and inter-assay variation. 
2.7. Statistics 
The data for experiments one through four were analyzed using MSD 
Workbench 4.0 software. The software calculates the working range of 
the assays by determining the Lower Level of Detection (LLOD) and the 
Upper Level of Detection (ULOD). Concentrations within these levels fall 
within the working range. 
For experiment five, variability was assessed by estimating the Co-
efficient of Variation CV;(Reed et al., 2002) Intra-assay CV were calcu-
lated from 36 available animal, day, and plate combinations with 
duplicate assays on the same plate and having values from 2 to 100, 
000 pg/mL. Five IL-1β combinations were removed for values greater 
than 100,000 pg/mL, one TNF-α sample did not produce a duplicate 
value, and three IL-6 values were less than 2 pg/mL. Assay CV were 
calculated from the SD of the two duplicates divided by the mean of the 
duplicates. The CVs for an assay were squared, summed, and then 
divided by number of samples. The square root of this value was an 
estimate of the intra-assay CV. Inter-assay CV was calculated from 16 
available animal and day combinations that had duplicate assays on 
different plates. Three IL-1 β duplicates were removed for values greater 
than 100,000 pg/mL, and two IL-6 duplicates had less than 2 pg/mL. 
Duplicates within a plate were averaged and SD of these averages across 
plates were calculated for each combination. The SD was divided by the 
average to estimate a CV for the 16 inter-plate assays. These CV were 
squared, summed, and divided by the number of combinations. The 
square root of this value was an estimate of the inter-assay CV. 
3. Results 
Experiment One: The dynamic range and sensitivity for both IL-1β 
C.G. Chitko-McKown et al.                                                                                                                                                                                                                   
Veterinary Immunology and Immunopathology 237 (2021) 110274
4
and TNF-α were better in singleplex than multiplex format (Table 1). 
The signal to background ratio (S:B; Relative Light Units - RLU) were 30 
and 70 RLU for IL-1β and TNF-α in singleplex, respectively, which 
decreased to 14 and 20 RLU respectively, for the multiplex. Background 
increased from 290 to 590 RLU from singleplex to multiplex for IL-1β 
and from 250 to 650 RLU for TNF-α. However, the sensitivities of the 
singleplex and multiplex formats were similar for both cytokines. The 
dynamic range and sensitivity of the bovine IL-6 assays were comparable 
in both formats, with the highest S:B of 30 RLU for singleplex and 14 
RLU for multiplex. The background signals were similar in both formats 
for this cytokine, as were the sensitivities. The sensitivities for all assays 
were in the pg/mL range, and the standard curves each had an r2 of 
greater than 0.99. All detection antibodies had a low non-specific 
binding to the IL-6 capture antibody; however, this was within a 
manageable level. 
Experiment Two: Decreasing the concentration of IL-6 detection 
antibody increased the S:B for both the IL-1β and TNF-α antibodies in all 
diluents tested, and 0.25μg/mL was determined to be the optimal con-
centration for the IL-6 detection antibody. However, compared to 1% 
BSA/PBS-T, using Diluent 7 or 8 resulted in higher background signals 
and lower sensitivity for TNF-α but lower background signals for IL-1β 
(Fig. 1). 
Experiment Three: The analytes could be detected at below 50 pg/ 
mL for all assays and excellent reproducibility was observed with both 
RPMI + 5% FBS and 1% BSA/PBS-T with % CVs of 11.1 and 7.8, 
respectively. (Tables 2 and 3). 
Experiment Four: Diluent 2 performed better than Diluent 7 when 
analyzing plasma samples. The differences noted between the two dil-
uents were observational. However, because it was determined that by 
diluting the plasma samples, we would no longer be able to measure IL-6 
in many samples due to the lower concentrations of IL-6 as compared to 
IL-1β and TNF-α, all plasma samples were analyzed undiluted (Table 4). 
Experiment five: Analysis of 280 plasma samples each run in dupli-
cate, half from healthy cattle and half from cattle presenting with BRDC, 
resulted in intra-assay CVs of 5.6 %, 3.6 %, and 4.2 %, and inter-assay 
CVs of 32.9 %, 28.0 %, and 18.0 % for IL-1β, IL-6, and TNF-α, respec-
tively. The CV became greater at the extreme ends of the standard 
curves. Only 37 out of 280 unique bovine serum samples assayed had IL- 
1β or TNF-α concentrations above the ULOD of these standard curves 
thus requiring the samples to be diluted, and only three samples had IL-6 
concentrations below the LLOD (Fig. 2). 
4. Discussion 
There are examples in the literature of researchers using the MSD 
platform to study bovine analytes. Mayers and Sawyer (2012) used this 
system to detect antibodies against four viral bovine respiratory disease 
pathogens. Jones et al. (2010) used an MSD multiplex to measure seven 
analytes important in Mycobacterium bovis infection in cattle. Coad et al. 
(2010) developed a bovine seven-plex to study the effect of repeated 
tuberculin skin testing on naturally infected tuberculous cattle. How-
ever, in these studies, the researchers relied on the company to custom 
prepare the assay plates. Tang et al. (2019) describe using the U-PLEX 
system to develop a multiplexed drug level assay thus showing the utility 
of this system for preparing custom assays within a research laboratory 
as compared to in MSD’s manufacturing facilities. 
Christopher-Henninge et al. (2013) list the numerous assay optimi-
zation steps that should be considered when developing immunoassays. 
These include identification of specific antibody pairs (either mono-
clonal or polyclonal), the identification of optimal buffering conditions, 
incubation times, optimal range of standards/calibrators, and compar-
isons made between singleplex and multiplex formats. The steps fol-
lowed in the development of the multiplex assay described in this study 
cover all these considerations. We obtained Do-It-Yourself ELISA kits 
that used the same polyclonal antibody for both the capture and the 
detection steps, thus eliminating the concern that two monoclonal an-
tibodies against the same analyte may bind to the same epitope 
(Christopher-Hennings et al., 2013). Using the U-PLEX chemistry and 
platform, the roles of these antibodies were reversed from the standard 
sandwich ELISA format. Various dilution buffers were tested for all 
stages of our U-PLEX assay, incubation times were validated, the range 
of our standards/calibrators were adjusted, and we compared the 
sensitivity of our assays in both singleplex and multiplex formats. 
Samples used to develop and validate this assay included cell culture 
supernatants from bovine monocytes that were either un-treated, or 
treated with LPS to stimulate inflammatory cytokine production, and 
plasma samples obtained from a group of feedlot cattle under study for 
BRDC. We chose this cohort of cattle because values for inflammatory 
cytokines should be low in healthy cattle and elevated in sick cattle. This 
provided us with a broad range of concentrations to measure in the assay 
and would indicate if our “optimal” concentrations selected for the 
standard curve were sufficient and would give us an indication if the 
dynamic range of the multiplex was sufficient to suit most samples. 
The MSD Workbench 4.0 software default calculates the ULOD as the 
highest standard concentration unless there is an obvious plateau in the 
top of the curve in which case it will calculate 2.5 Std deviations below 
the top standard. The LLOD is calculated as 2.5 Std deviations above the 
background signal, so this will change for each run based on the preci-
sion of those background signals. In our experiments the ULOD of the 
standards/calibrators were consistently listed as the highest concentra-
tion included in the standard curves. Several plasma samples fell below 
the LLOD of the IL-6 assay however, no sample were below LLOD for IL- 
1β and TNF-α. In contrast, several samples were above the ULOD for IL- 
1β and TNF-α. Diluting serum samples can result in a reduction of matrix 
background (Juncker et al., 2014; Leng et al., 2008), but due to the 
differences in plasma concentrations between IL-6 and the other two 
cytokines, dilution of our samples at even 1:2 would have resulted in 
many samples being below the LLOD for IL-6. The differences in ranges 
of analyte concentrations should be considered when developing 
multiplex assays for this reason (Dudal et al., 2014; Leng et al., 2008). It 
appears that STD 1 for IL-1β and TNF-α may require a higher concen-
tration than 50,000 pg/mL when analyzing samples from animals 
suffering from inflammation, however, we did not attempt it in these 
experiments. For studies where concentrations are hypothesized to be 
higher than in normal samples, this increase should be considered. We 
used four-fold serial dilutions to prepare our standard curves, and it may 
be possible to start with a higher maximum concentration and use a 
larger dilution to increase the range of the standards for IL-1β and 
TNF-α while still using seven calibrator dilutions and one with buffer 
only. 
5. Conclusions 
We show that commercially available "Do-It-Yourself" ELISA kits can 
be adapted to the Meso Scale Discovery U-PLEX platform to develop 
custom multiplex assays. Our U-PLEX assay for the bovine cytokines IL- 
1β, IL-6, and TNF-α produced consistent, high quality data with intra- 
and inter-assay variation within acceptable ranges. Although there are 
Table 1 
Summary of the limits of detection (LLOD, ULOD) for each assay format and 

















20.1 23.2 4.2 1.8 29.0 43.4 
ULOD (pg/ 
mL) 




2.7 2.6 3.4 3.7 2.5 2.4 
%CV Signal 2.3 2.0 4.0 1.8 3.5 2.6  
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few commercially available multiplex assays for species others than 
rodents and humans, the availability of monoclonal and polyclonal an-
tibodies and recombinant proteins specific for other species are 
becoming more abundant. By using these reagents within the U-PLEX 
system, researchers can more easily develop multiplex assays for their 
specific needs. 
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Fig. 1. Signal to Background (S:B) showing the highest S:B in red and the lowest S:B in green. Maximum S:B for all cytokines was obtained when the IL-6 detection 
antibody was used at 0.25μg/mL. 
Table 2 
Summary of the lower, and upper limits of detection (LLOD, ULOD) for each 
assay format and shows the dynamic range and reproducibility of the standards 
for each assay when different sample diluents (1%BSA/PBS-T vs RPMI + 5% 
FBS).  
U-PLEX 3-Assay 1%BSA/PBS-T RPMI + 5%FBS  
IL-1β IL-6 TNF-α IL-1β IL-6 TNF-α 
LLOD (pg/mL) 17.0 1.5 38.3 5.2 1.3 14.5 
ULOD (pg/mL) 50,000 10,000 50,000 50,000 10,000 50,000 
Dynamic Range 
(log) 
3.5 3.8 3.1 4.0 3.9 3.5 
Calc Conc. %CV 13.3 2.7 7.2 22.8 2.5 8.2  
Table 3 
Calculated concentration means and calculated concentration %CV for bovine 
monocyte tissue culture supernatant sample either unstimulated or stimulated 
with LPS.  
Sample ID Calculated Concentration Means Calculated Concentration %CV  
IL-1β IL-6 TNF-α IL-1β IL-6 TNF-α 
386 Control 30.1 20.5 60.4 21.1 2.8 18.9 
386 LPS 137.5 63.5 2,244.9 5.6 0.7 2.0 
455 Control 13.2 31.3 123.3 5.4 0.3 3.8 
455 LPS 403.2 94.6 4,812.9 2.4 0.5 5.0 
602 Control 81.2 87.1 316.9 0.4 0.1 1.9 
602 LPS 1,932.0 214.5 7,935.2 1.6 1.0 0.1  
Table 4 
Calculated intra- and inter-assay %CV for 36 and 16 bovine plasma samples 
respectively, run over at least 2 plates.  
U-PLEX 3-Assay Calculated Concentration %CV  
IL-1β IL-6 TNF-α 
Intra-assay %CV 5.6 3.6 4.2 
Inter-assay %CV 32.9 28.0 18.0  
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Taniguchi, Y., Yang, J., 2014. Assay formats: recommendation for best practices and 
harmonization from the Global Consortium Harmonization Team. AAPS J. 16, 
194–205. 
Jones, G.J., Pirson, C., Hewinson, R.G., Voedermeirer, H.M., 2010. Simultaneous 
measurement of antigen-stimulated intereukin-1β and gamma interferon production 
enhances test sensitivity for the detection of Mycobacterium bovis infection in cattle. 
Clin. Vaccine Immunol. 17, 1946–1951. 
Juncker, D., Bergeron, S., Laforte, V., Li, H., 2014. Cross-reactivity in antibody 
microarrays and multiplexed sandwich assays: shedding light on the dark side of 
multiplexing. Curr. Opin. Chem. Biol. 18, 29–37. 
Lea, P., Keystone, E., Mudumba, S., Kahama, A., Ding, S.-F., Hansen, J., Azad, A.A., 
Wang, S., Weber, D., 2011. Advantages of multiplex proteomics in clinical 
immunology: The case of rheumatoid arthritis: novel IgXPLEXTM planar microarray 
diagnosis. Clin. Rev. Allergy Immunol. 41, 20–35. 
Leng, S.X., McElhaney, J.E., Walston, J.D., Xie, D., Fedarko, N.S., Kuchel, G.A., 2008. 
ELISA and multiplex technologies for cytokine measurement in inflammation and 
aging research. J. Gerontol. A Biol. Sci. Med. Sci. 63, 879–884. 
Mayers, J., Sawyer, J., 2012. Development and evaluation of a multiplex enzyme-linked 
immunosorbent assay for the detection of antibodies to bovine respiratory diseases 
on the Meso Scale Discovery platform. J. Vet. Diagn. Invest. 24, 725–729. 
Reed, G.F., Lynn, F., Meade, B.D., 2002. Use of coefficient of variation in assessing 
variability of quantitative assays. Clin. Diagn. Lab. Immunol. 9, 1235–1239. 
Tang, H., Shah, K., Steinmetz, T., Abraham, A., Jensen, H., Bouyton, A., Marullo, K., 
Shi, S., 2019. Development and validation of a multiplexed drug level assay in 
support of combination biologics therapy clinical studies. J. Pharm. Biomed. Anal. 
171, 204–211. 
Tighe, P.J., Ryder, R.R., Todd, I., Fairclough, L.C., 2015. ELISA in the multiplex era: 
potentials and pitfalls. Proteomics Clin. Appl. 9, 406–422. 
Fig. 2. Representative standard curves for the multiplex assay for bovine IL-1β, IL-6, and TNF-α with bovine plasma samples from healthy cattle, or animals pre-
senting with bovine respiratory disease serving as unknowns. 
C.G. Chitko-McKown et al.                                                                                                                                                                                                                   
